一种创新工具,用于优先评估在研 COVID-19 疗法:试点项目。

Lizanne Béïque, Savannah Clarke, Mina Azad, Elaha Sarwar, Margaret Gale-Rowe, Stacy Sabourin, Cheryl Marinsky, Jacqueline Arthur
{"title":"一种创新工具,用于优先评估在研 COVID-19 疗法:试点项目。","authors":"Lizanne Béïque, Savannah Clarke, Mina Azad, Elaha Sarwar, Margaret Gale-Rowe, Stacy Sabourin, Cheryl Marinsky, Jacqueline Arthur","doi":"10.14745/ccdr.v50i10a04","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>As the COVID-19 pandemic unfolded, hundreds of investigational COVID-19 therapeutics emerged. Maintaining situational awareness of this extensive and rapidly evolving therapeutic landscape represented an unprecedented challenge for the Public Health Agency of Canada, as it worked to promote and protect the health of Canadians. A tool to triage and prioritize the assessment of these therapeutics was needed.</p><p><strong>Methods: </strong>The objective was to develop and conduct an initial validation of a tool to identify investigational COVID-19 therapeutics for further review based on an efficient preliminary assessment, using a systematic and reliable process that would be practical to validate, implement and update. Phase 1 of this pilot project consisted of a literature search to identify existing COVID-19 therapeutic assessment prioritization tools, development of the Rapid Scoring Tool (RST) and initial validation of the tool.</p><p><strong>Results: </strong>No tools designed to rank investigational COVID-19 therapeutics for the purpose of prioritizing their assessment were identified. However, a few publications provided criteria to consider and therapeutic ranking methods, which helped shape the development of the RST. The RST included eight criteria and several descriptors (\"characteristics\"). A universal characteristic scoring scale from -10 to 10 was developed. The sum of all the characteristic scores yielded an overall benefit score for each therapeutic. The RST appropriately ranked therapeutics using a systematic, reliable and practical approach.</p><p><strong>Conclusion: </strong>Phase 1 was successfully completed. The RST presents several distinct aspects compared with other tools, including its scoring scale and method, and capacity to factor in incomplete or pending information. It is anticipated that the framework used for the RST will lend itself to use in other dynamic situations involving many interventions.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 10","pages":"357-364"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460842/pdf/","citationCount":"0","resultStr":"{\"title\":\"An innovative tool to prioritize the assessment of investigational COVID-19 therapeutics: A pilot project.\",\"authors\":\"Lizanne Béïque, Savannah Clarke, Mina Azad, Elaha Sarwar, Margaret Gale-Rowe, Stacy Sabourin, Cheryl Marinsky, Jacqueline Arthur\",\"doi\":\"10.14745/ccdr.v50i10a04\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>As the COVID-19 pandemic unfolded, hundreds of investigational COVID-19 therapeutics emerged. Maintaining situational awareness of this extensive and rapidly evolving therapeutic landscape represented an unprecedented challenge for the Public Health Agency of Canada, as it worked to promote and protect the health of Canadians. A tool to triage and prioritize the assessment of these therapeutics was needed.</p><p><strong>Methods: </strong>The objective was to develop and conduct an initial validation of a tool to identify investigational COVID-19 therapeutics for further review based on an efficient preliminary assessment, using a systematic and reliable process that would be practical to validate, implement and update. Phase 1 of this pilot project consisted of a literature search to identify existing COVID-19 therapeutic assessment prioritization tools, development of the Rapid Scoring Tool (RST) and initial validation of the tool.</p><p><strong>Results: </strong>No tools designed to rank investigational COVID-19 therapeutics for the purpose of prioritizing their assessment were identified. However, a few publications provided criteria to consider and therapeutic ranking methods, which helped shape the development of the RST. The RST included eight criteria and several descriptors (\\\"characteristics\\\"). A universal characteristic scoring scale from -10 to 10 was developed. The sum of all the characteristic scores yielded an overall benefit score for each therapeutic. The RST appropriately ranked therapeutics using a systematic, reliable and practical approach.</p><p><strong>Conclusion: </strong>Phase 1 was successfully completed. The RST presents several distinct aspects compared with other tools, including its scoring scale and method, and capacity to factor in incomplete or pending information. It is anticipated that the framework used for the RST will lend itself to use in other dynamic situations involving many interventions.</p>\",\"PeriodicalId\":94304,\"journal\":{\"name\":\"Canada communicable disease report = Releve des maladies transmissibles au Canada\",\"volume\":\"50 10\",\"pages\":\"357-364\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460842/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canada communicable disease report = Releve des maladies transmissibles au Canada\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14745/ccdr.v50i10a04\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canada communicable disease report = Releve des maladies transmissibles au Canada","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14745/ccdr.v50i10a04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:随着 COVID-19 大流行的发展,出现了数百种 COVID-19 研究疗法。加拿大公共卫生局致力于促进和保护加拿大人的健康,而保持对这一广泛且快速发展的治疗领域的态势感知则是一项前所未有的挑战。我们需要一种工具来对这些疗法进行分流和优先评估:方法:我们的目标是开发并初步验证一种工具,以便在高效初步评估的基础上,利用系统、可靠且易于验证、实施和更新的流程,确定需要进一步审查的 COVID-19 研究性疗法。该试点项目的第一阶段包括文献检索以确定现有的 COVID-19 治疗评估优先级工具、开发快速评分工具 (RST) 以及对该工具进行初步验证:结果:未发现任何旨在对在研 COVID-19 疗法进行排序以确定其评估优先次序的工具。不过,一些出版物提供了考虑标准和治疗排序方法,有助于 RST 的开发。RST 包括八项标准和若干描述符("特征")。制定了一个从 -10 到 10 的通用特征评分表。所有特征得分的总和得出每种疗法的总体效益得分。RST 采用系统、可靠和实用的方法对疗法进行了适当的排序:第一阶段已顺利完成。与其他工具相比,RST 有几个与众不同之处,包括其评分标准和方法,以及考虑不完整或待定信息的能力。预计 RST 所使用的框架可用于其他涉及多种干预措施的动态情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
An innovative tool to prioritize the assessment of investigational COVID-19 therapeutics: A pilot project.

Background: As the COVID-19 pandemic unfolded, hundreds of investigational COVID-19 therapeutics emerged. Maintaining situational awareness of this extensive and rapidly evolving therapeutic landscape represented an unprecedented challenge for the Public Health Agency of Canada, as it worked to promote and protect the health of Canadians. A tool to triage and prioritize the assessment of these therapeutics was needed.

Methods: The objective was to develop and conduct an initial validation of a tool to identify investigational COVID-19 therapeutics for further review based on an efficient preliminary assessment, using a systematic and reliable process that would be practical to validate, implement and update. Phase 1 of this pilot project consisted of a literature search to identify existing COVID-19 therapeutic assessment prioritization tools, development of the Rapid Scoring Tool (RST) and initial validation of the tool.

Results: No tools designed to rank investigational COVID-19 therapeutics for the purpose of prioritizing their assessment were identified. However, a few publications provided criteria to consider and therapeutic ranking methods, which helped shape the development of the RST. The RST included eight criteria and several descriptors ("characteristics"). A universal characteristic scoring scale from -10 to 10 was developed. The sum of all the characteristic scores yielded an overall benefit score for each therapeutic. The RST appropriately ranked therapeutics using a systematic, reliable and practical approach.

Conclusion: Phase 1 was successfully completed. The RST presents several distinct aspects compared with other tools, including its scoring scale and method, and capacity to factor in incomplete or pending information. It is anticipated that the framework used for the RST will lend itself to use in other dynamic situations involving many interventions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信